Seems like CREDENCE trial results were just presented at the ISN World Congress of Nephrology in Melbourne and published in NEJM. Canagliflozin SGLT2 inhibitor in diabetics with CKD. Impressive results. Also nice write up by John Carroll in Endpoints News. Looking forward to the CKD sub-study of BETonMACE to potentially steal the spotlight by impressing even more.